Acute myeloid leukemia, MLL gene rearrangement

This phase 3 trial is testing whether adding revumenib, a drug that blocks a protein called menin, to the usual two-drug combination (azacitidine and venetoclax) can improve outcomes for adults newly diagnosed with acute myeloid leukemia (AML) that has a specific genetic change (…

This phase 3 trial tests whether adding the drug bleximenib to standard chemotherapy helps adults with a certain genetic type of acute myeloid leukemia (AML). About 875 people will get either bleximenib or a placebo alongside chemo, then be followed for 4 years. The goal is to se…

This study tests whether adding the experimental drug bleximenib to standard treatment (venetoclax and azacitidine) helps people with a specific genetic subtype of acute myeloid leukemia (AML) achieve remission and live longer. The trial enrolls 600 adults aged 18 and older who h…

This study tests a drug called ziftomenib in 70 adults with acute myeloid leukemia (AML) who have specific gene changes (NPM1 or KMT2A) and cannot receive standard chemotherapy. Ziftomenib blocks a protein called menin that helps cancer cells grow. The goal is to see if the drug …

This early-phase trial tests whether adding a menin inhibitor (SNDX-5613) to standard chemotherapy can better control acute myeloid leukemia (AML) in people with certain gene changes (NPM1 or MLL). About 38 newly diagnosed adults will receive the combination to find the safest do…

This early-stage trial is testing a new drug called ziftomenib combined with standard chemotherapy or another targeted drug for people with relapsed or treatment-resistant acute myeloid leukemia (AML) that has specific genetic changes. The main goal is to see if these combination…

This large Phase 3 trial is testing whether adding the experimental drug ziftomenib to standard chemotherapy helps people with untreated acute myeloid leukemia (AML) who have specific genetic mutations. About 1,300 participants will be randomly assigned to receive either ziftomen…

This phase 2 trial tests whether giving patients their own personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill any remaining cancer cells. The study includes 100 people with various blood cancers like leukemia, lymphoma, and multipl…

This study tests whether giving children with leukemia a special type of donor immune cell (CD45RA-depleted) after a stem cell transplant can help their immune system recover faster and lower the risk of serious viral or fungal infections. The trial enrolls 50 children under 25 w…

This program provides expanded access to the experimental drug ziftomenib for adults with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has specific genetic changes (KMT2A rearrangements or NPM1 mutations). It is for patients who have exhausted standard …

This early-phase study tests whether combining two targeted drugs, SNDX-5613 and gilteritinib, is safe and effective for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The drugs work by blocking different signals that …

This early-stage trial is testing an experimental drug called ziftomenib alongside standard treatments for acute myeloid leukemia (AML) in people with specific gene mutations. About 420 participants with newly diagnosed or relapsed AML will be assigned to one of three treatment a…

This early-phase trial tests a drug called revumenib in people with acute leukemia who have had a stem cell transplant. The drug targets a protein that helps leukemia cells grow. The study will check safety, find the best dose, and see if it can stop the cancer from coming back. …

This early-phase trial tests a new drug called ziftomenib, taken as a capsule, together with standard chemotherapy (cytarabine and fludarabine) for children and young adults up to age 21 who have a relapsed or refractory acute leukemia with specific genetic changes (KMT2A-r, NUP9…

This study looks at blood cells from 20 adults with acute myeloid leukemia (AML) whose cancer returned after a stem cell transplant. All participants have specific genetic changes (NPM1 mutations or KMT2A rearrangements) and are being treated with a menin inhibitor. Researchers w…

This observational study looks at whether leukemia stem cells can predict if acute myeloid leukemia (AML) with MLL rearrangement will come back. Researchers will measure these stem cells in bone marrow samples taken during regular check-ups. The goal is to improve relapse predict…